Respiratory Phase 3 Readout Calendar
Industry-sponsored respiratory trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
17
Next 6 months
28
Next 12 months
21
Results posted
148
Phase 3 Respiratory
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 respiratory trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What respiratory trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 respiratory trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which respiratory trials have already read out?
The "recently read out" section shows Phase 3 respiratory trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Respiratory slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Respiratory landscape →
Recently read out & awaiting topline — Respiratory
· 14Phase 3 respiratory trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | Active Not Recruiting | Q1 2026 2026-03-06 | Completed · awaiting
Updated 4mo ago
| NCT06040086 |
| AstraZeneca | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-02-26 | Completed · awaiting
Updated 4mo ago
| NCT05742802 |
| United Therapeutics | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Asset: Placebo | Idiopathic Pulmonary Fibrosis +1 | Completed | Q1 2026 2026-02-02 | Completed · awaiting
Updated 3mo ago
| NCT04708782 |
| Vertex Pharmaceuticals Incorporated | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older Asset: ELX/TEZ/IVA | Cystic Fibrosis | Completed | Q1 2026 2026-01-29 | Completed · awaiting
Updated 5mo ago
| NCT05153317 |
| AstraZeneca | A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Asset: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate | Chronic Obstructive Pulmonary Disease | Completed | Q1 2026 2026-01-22 | Completed · awaiting
Updated 4mo ago
| NCT06067828 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-01-19 | Completed · awaiting
Updated 3mo ago
| NCT05166889 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-01-19 | Completed · awaiting
Updated 3mo ago
| NCT05158387 |
| Chiesi Farmaceutici S.p.A. | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Asset: Beclomethasone Dipropionate | COPD +1 | Completed | Q1 2026 2026-01-12 | Completed · awaiting
Updated 6mo ago
| NCT04320342 |
| GlaxoSmithKline | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Asset: GSK3511294 (Depemokimab) | Asthma | Completed | Q3 2025 2025-09-14 | Completed · awaiting
Updated 9mo ago
| NCT04718389 |
| Vertex Pharmaceuticals Incorporated | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age Asset: ELX/TEZ/IVA | Cystic Fibrosis | Completed | Q3 2025 2025-09-04 | Completed · awaiting
Updated 9mo ago
| NCT05882357 |
| GlaxoSmithKline | A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma Asset: Salbutamol HFA-134a | Asthma | Completed | Q3 2025 2025-09-02 | Completed · awaiting
Updated 5mo ago
| NCT06261957 |
| Meiji Seika Pharma Co., Ltd. | P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Asset: co-administration of cefepime and nacubactam | Complicated Urinary Tract Infection +4 | Completed | Q3 2025 2025-09-01 | Completed · awaiting
Updated 3mo ago
| NCT05905055 |
| AstraZeneca | A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD Asset: BGF MDI HFO 320/14.4/9.6μg | COPD (Chronic Obstructive Pulmonary Disease) | Completed | Q3 2025 2025-08-12 | Completed · awaiting
Updated 11mo ago
| NCT06075095 |
| AstraZeneca | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations Asset: Benralizumab | Chronic Obstructive Pulmonary Disease | Completed | Q3 2025 2025-07-28 | Completed · awaiting
Updated 11mo ago
| NCT04053634 |
Upcoming respiratory readouts — next 12 months
· 28Industry Phase 3 respiratory trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| ALK-Abelló A/S | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 Asset: HDM SLIT-tablet (12 SQ-HDM) | Allergic Rhinoconjunctivitis +1 | Active Not Recruiting | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT07060885 |
| Daewon Pharmaceutical Co., Ltd. | Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma Asset: Experimental | Perennial Allergic Rhinitis Accompanied by Asthma | Recruiting | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 10mo ago
| NCT07168473 |
| Eli Lilly and Company | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) Asset: LY3650150 | Perennial Allergic Rhinitis (PAR) | Recruiting | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 3mo ago
| NCT06339008 |
| Bristol-Myers Squibb | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Asset: BMS-986278 | Idiopathic Pulmonary Fibrosis | Active Not Recruiting | Q4 2026 2026-10-06 (est.) | Estimated · fresh
Updated 4mo ago
| NCT06003426 |
| Vertex Pharmaceuticals Incorporated | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Asset: VX-121/TEZ/D-IVA | Cystic Fibrosis | Active Not Recruiting | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT05444257 |
Unlock 23 more respiratory readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.